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Abstract: This paper reviews the results of placebo-controlled trials on topiramate (TPM) in 
the prophylaxis of migraine, focusing particularly on efﬁ  cacy and tolerability of the target dose 
(100 mg/day). Data from well-conducted trials and analyses of pooled data show that TPM is 
effective against migraine, conﬁ  rming the experience of physicians in various countries. High 
responder rate and good tolerability following slow titration suggest TPM as a ﬁ  rst-line option 
for migraine prophylaxis. Patient acceptability may be enhanced by lack of weight gain, lack 
of major contraindications, and positive effects on quality of life.
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Introduction
Migraine is a chronic neurological disorder characterized by recurrent attacks of 
headache and other symptoms which may last up to 3 days. The pain is moderate to 
severe, and is associated with other symptoms, such as phonophobia, photophobia, 
nausea, and vomiting. Prodromes like somnolence and mood changes may also be 
present. In some patients the headache phase is preceded by aura, a complex of focal 
neurological symptoms, which may include visual disturbances, numbness, paresthesia, 
and speech difﬁ  culties (Headache Classiﬁ  cation Subcommittee of the International 
Headache Society 2004; Lipton et al 2000).
Migraine is a widespread disorder and tends to be present for long periods in 
patients’ lives producing a wide range of impacts on personal and social functioning 
(Stewart et al 1994; Lipton, Hamelsky, et al 2001). The prevalence rate of migraine 
with or without aura in the US in 1999 was 12.6% overall and 18.2% in women com-
pared with 6.5% in men (Lipton, Stewart, et al 2001). Similar estimates have been 
reported by various population-based studies from other countries (Launer et al 1999; 
Roncolato et al 2000; Lipton, Hamelsky, et al 2001; Henry et al 2002; Steiner et al 
2003). Such surveys indicate that migraine prevalence increases steadily with age, 
particularly in women, and peaks between the mid thirties and mid forties – the peak 
years of personal and professional activity.
About a half of migraineurs in the general population surveyed in a Canadian 
study (Edmeads et al 1993) and in the second American Migraine Study (Lipton, 
Stewart, et al 2001) reported that their severe headaches led to substantial impairment 
or discontinuation of their daily activities, and required bed rest in many cases. These 
ﬁ  nding are supported by population and clinical studies which show that migraineurs 
are affected in work and nonwork activities, and may manifest not only as absence 
from the workplace but also as substantially reduced productivity in paid work and 
household work, as well as disruption of relations with family and friends, and social 
and leisure activities (von Korff et al 1998; Brandes 2002; Bigal et al 2003; D’Amico, Neuropsychiatric Disease and Treatment 2006:2(3) 262
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Genco, et al 2004; D’Amico, Usai, et al 2004; Dueland et al 
2004; MacGregor et al 2004).
Migraine also has a pervasive negative inﬂ  uence on 
patient well-being during headache-free periods, as mani-
fested by compromised physical, mental, emotional, and 
social functioning. These health-related quality of life 
(HRQOL) effects have been extensively studied (Dahlöf 
and Dimenäis 1995; Solomon and Santanello 2000; Lipton 
et al 2003; D’Amico, Usai, et al 2004; Dueland et al 2005). 
HRQOL in migraineurs is poor in comparison with people 
without migraine, and it seems to be worse than that expe-
rienced by people with several other chronic disorders 
(myocardial infarction, diabetes, hypertension, and asthma) 
(Osterhaus et al 1992; Terwindt et al 2000).
The prevalence ﬁ  gures and the results of studies assessing 
the functional consequences of migraine indicate that the 
disorder has major negative effects on individuals and on 
society as a whole, so that effective migraine management 
is an important priority of both general practitioners and 
neurologists.
Acute treatments should be taken during migraine 
attacks to reduce the severity and duration of the episodes. 
Migraine patients with high attack frequency, unsatisfac-
tory response to acute treatment, or who overuse acute 
medications are candidates for prophylactic treatments 
(Silberstein 2000; Silberstein et al 2001; Dowson et al 
2002), which are taken daily with the aim of reducing the 
frequency, duration, and severity of attacks, and ultimately 
improving quality of life and ability to function in daily 
activities.
Various drugs are currently used for migraine prophylaxis, 
including β-blockers, antidepressants, calcium channel antag-
onists, serotonin antagonists, and anti-epileptics (Gray et al 
1999; Silberstein et al 2001). However, many of the studies 
conducted with these drugs did not adhere to the criteria 
proposed by the International Headache Society (Inter-
national Headache Society Clinical Trials Subcommittee 
2000), and by the US Headache Consortium guidelines 
(Silberstein 2000) for conducting trials with preventive 
migraine compounds and validating their use in migraine 
patients. These criteria require that preventive treatments 
should be validated using evidence-based standards, and 
in particular that efficacy should be supported by data 
from large, well-designed, placebo-controlled trials. Such 
trials should assess prophylactic efﬁ  cacy (which must be 
sustained), safety, and tolerability. Furthermore the treatment 
should not worsen comorbid conditions, and side-effects 
should not impede compliance.
Topiramate (TPM) is a neuromodulatory drug with 
unique pharmacological and clinical proﬁ  les. TPM has 
emerged relatively recently as a treatment for migraine, and 
is approved for migraine prevention in several countries 
including the US.
We review here the pharmacology of TPM and also 
the results of large well-conducted trials of TPM in 
migraine patients, focusing particularly on efficacy and 
tolerability of the target dose of this drug in migraine prevention 
(100 mg/day). We also discuss data and issues pertaining to 
patient satisfaction (quality of life and acceptability).
Pharmacology and mode of action
TPM bioavailability after oral assumption is greater 
than 80%. Maximum plasma levels (Cmax) are reached 1.3–1.7 
hours after oral administration, and half-life is 19–23 hours. 
Protein binding is around 15%; 50%–80% of the drug is 
excreted unchanged in the urine.
TPM possesses a broad clinical spectrum of activity. 
Animal studies and clinical trials have led to its indication 
in epilepsy, as adjunctive therapy and now also as 
monotherapy (Silberstein et al 2005). Pilot studies and 
small controlled trials have assessed its efﬁ  cacy in several 
psychiatric conditions, including binge-eating disorders 
(McElroy et al 2003) and alcohol dependence (Johnson 
et al 2003).
TPM was introduced as a treatment for migraine 
prophylaxis on the basis of results from controlled trials 
(Brandes et al 2004; Diener et al 2004; Silberstein et al 
2004). Although the exact mechanisms by which it is 
effective in migraine have not been established, several 
effects of TPM may contribute to its anti-migraine action. 
Migraine is a neurovascular disorder characterized by a state 
of neuronal hyperexcitability, with abnormal modulation 
involving several receptors and ion channels at several 
sites including the cerebral cortex, the trigeminovascular 
system, and brainstem nuclei (Goadsby 2005; Welch 
2005). TPM inhibits the excitatory effect of glutamate 
at α-amino-3-hydroxy-5-methylisoxazole-4-propionic 
acid–kainite receptor subtypes; it enhances chloride ﬂ  ux 
mediated by the inhibitory γ-aminobutyric acid receptor A; 
it inhibits voltage-gated sodium channels and high-voltage-
gated calcium channels; and it also inhibits some subtypes 
of the enzyme carbonic anhydrase (Shank et al 2000). 
TPM may therefore exert a variety of pharmacodynamic 
effects in migraineurs that could explain its efﬁ  cacy such 
as reducing cortical hyperexcitability that leads to cortical 
spreading depression, inhibiting glutamatergic signaling Neuropsychiatric Disease and Treatment 2006:2(3) 263
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by trigeminal afferent nerves, or modulating nociceptive 
signaling through GABA-receptors in the trigeminal 
nucleus caudalis or in descending brain pathways (Shank 
et al 2000).
Efﬁ  cacy
The two pivotal studies conducted to determine the efﬁ  cacy 
of TPM in migraine prevention are MIGR-001, conducted 
at 49 sites in the US (Silberstein et al 2004), and MIGR-002, 
conducted at 52 US and Canadian centers (Brandes et al 
2004). Both these studies were randomized, double-blind, 
placebo-controlled trials. The treatment period was 26 weeks, 
divided into an 8-week titration phase and an 18-week 
maintenance phase. Three daily doses were tested: 50, 100, 
or 200 mg. In all cases, TPM was started at 25 mg/day 
and titrated to target dose or maximum tolerated dose at 
the rate of 25 mg/week. Efﬁ  cacy was assessed throughout 
the double-blind period, including the titration period. The 
primary efﬁ  cacy measure was change in mean monthly 
migraine frequency compared with baseline, assessed using 
migraine periods, ie, migraine headache that started and 
ended or recurred and ended within 24 hours. Secondary 
efﬁ  cacy endpoints included the percentage of responders 
(proportion with  50% reduction in the monthly migraine 
frequency), and the time to onset of action. The intent-to-treat 
populations were 469 patients in MIGR-001 and 468 patients 
in MIGR-002.
The results of these trials showed that TPM treatment was 
associated with signiﬁ  cant improvements in the 100 mg/day 
and in the 200 mg/day arms. Reductions in monthly migraine 
frequency were signiﬁ  cantly higher than in the placebo arm 
(p   0.001 for both doses in MIGR-001; p = 0.008 in the 
100 mg/day arm, and p = 0.001 in the 200 mg/day arm in 
MIGR-002). Furthermore there were signiﬁ  cantly more 
responders in both dosage arms than in the placebo arm 
(p   0.001 for both dosages, MIGR-001 and MIGR-002 
studies).
Thus it emerged that 200 mg/day TPM was not more 
effective than 100 mg/day TPM. For example, in MIGR-001, 
migraine frequency decreased from 5.4 ± 2.2 days/month 
at baseline to 3.3 ± 2.9 days/month during the double-
blind phase with 100 mg/day TPM, and from 5.6 ± 2.6 to 
3.3 ± 2.9 days/month with 200 mg/day TPM; the responder 
rate was 54% for 100 mg/day, and 52.3% for 200 mg/day.
In both MIGR studies, patients in the 50 mg/day arm had 
reductions in migraine frequency but responders were fewer 
than with higher daily doses, and did not differ signiﬁ  cantly 
from those found in the placebo arm.
The MIGR-003 trial was a randomized, double-blind, 
multicenter comparative trial (61 sites, 13 countries) 
evaluating 575 migraine patients as the intent-to-treat 
population. The trial was designed to assess the efﬁ  cacy 
and safety of TPM vs placebo in migraine prophylaxis, 
and used propranolol as active control (Diener et al 
2004). Patients were randomized to TPM (100 mg/day or 
200 mg/day), propranolol (160 mg/day), or placebo. The 
trial results were substantially in agreement with those 
of the two previous MIGR trials: TPM was superior to 
placebo in reducing monthly migraine frequency and 
in increasing responder rate. The 100 mg/day TPM 
and propranolol groups were characterized by similar 
reductions in migraine frequency, responder rate, and 
daily use of rescue medication.
The overall results of these three studies indicate that 
100 mg/day is more effective than the 50 mg/day, and that 
200 mg/day does not provide a clear additional beneﬁ  t. Based 
on these results it was concluded that 100 mg/day of TPM is 
the target dose in migraine prevention.
The protocols of the three trials ( Brandes et al 2004; 
Diener et al 2004; Silberstein et al 2004) were similar in 
design and had the same primary and secondary endpoints. 
The data from these studies have been pooled to evaluate the 
consistency of efﬁ  cacy of 100 mg/day TPM (386 patients) 
vs placebo (372 patients) (Bussone et al 2005; Silberstein 
et al 2005). These analyses showed that TPM is superior 
to placebo, and that efﬁ  cacy always emerged irrespective 
of the assessment method (migraine periods, number 
of migraine attacks, or number of days with migraine). 
Thus, the decrease in mean monthly number of migraine 
periods from baseline to endpoint was signiﬁ  cant (mean 
change −2.0 ± 0.16 in the TPM arm, −1.0 ± 0.13 in the 
placebo arm, p   0.001) (Figure 1). Similarly, TPM 
treatment was associated with a signiﬁ  cant reduction in 
migraine attack frequency (−1.7 ± 0.16 vs −0.8 ± 0.13; 
p   0.001), and in monthly migraine days (−2.4 ± 0.18 
vs −1.2 ± 0.16; p   0.001). Monthly migraine duration 
also decreased during the treatment periods in all the three 
clinical trials, with a mean reduction of −0.9 ± 0.09 hours in 
the TPM arms compared with −0.5 ± 0.08 hours in patients 
who received placebo (p   0.05).
Although about half of the patients receiving TPM 
achieved at least a 50% reduction in monthly number 
of migraine periods, it is important to note that one in 
four patients obtained the greater clinical beneﬁ  t of at least 
a 75% reduction (Figure 2); furthermore 5.8% of patients 
became free of migraine periods and migraine days.Neuropsychiatric Disease and Treatment 2006:2(3) 264
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Other important ﬁ  ndings of the pooled analysis were that 
monthly migraine frequency declined progressively over 
time, as shown in Figure 1: a signiﬁ  cant difference between 
TPM and placebo was achieved as early as the ﬁ  rst month 
(by which time the target dose of 100 mg/day had been 
reached) and the improvement continued steadily throughout 
the double-blind period. Improvement rates were similar in 
males and females.
Tolerability
Pooled data from the above-mentioned controlled studies 
(Bussone et al 2005; Silberstein et al 2005) show that 
paresthesia is the most common adverse event, being reported 
in 51% of patients on TPM 100 mg/day, in 49% of those on 
200 mg/day, and by 6% of patients on placebo.
Fatigue was the second most common adverse event, 
being reported by 11% of patients on placebo, and slightly 
more patients on TPM (15% for TPM 100 mg/day, and 19% 
for in TPM 200 mg/day).
The incidence of adverse central nervous system events 
in migraine patients was also low: somnolence, insomnia, 
memory or concentration difﬁ  culties, language problems, 
and mood changes were present in 2%–5% of patients on 
placebo, 6%–7% of patients on TPM 100 mg/day, and 
7%–12% of those on TPM 200 mg/day; while 8% of patients 
on TPM 100 mg/day and 12% of those on 200 mg/day TPM 
complained of taste perversion, compared with 1% of patients 
on placebo. The rates of these adverse events were generally 
lower in patients receiving 50 mg/day TPM.
The most common adverse events in patients receiving 
different doses of TPM in controlled clinical trials (pooled 
data from Silberstein et al 2005) are shown in Table 1.
Overall discontinuation rates were quite high: about 25% 
in patients on 100 mg/day TPM and about 40% in those on 
200 mg/day. The percentages of patients who withdrew from 
clinical trials because of each adverse event are shown in 
Table 1.
In patients on 100 mg/day TPM, discontinuation was for 
paresthesia in 8%, fatigue in 5%, insomnia in 3%, and for other 
symptoms (nausea, anorexia, dizziness, and concentration 
difﬁ  culties) in about 2% each.
Other side-effects may occur rarely after TPM exposure 
(Brandes 2005). Kidney stone formation is a rare adverse 
event. Metabolic acidosis is a possibility when predisposing 
conditions are present. Such conditions include kidney disease, 
severe respiratory disorder, status epilepticus, diarrhea, surgery, 
ketogenic diet, and use of other carbonic anhydrase inhibitors. 
Hyperthermia may occur, especially in children doing physical 
exercise, or after exposure to high ambient temperature. Patients 
should be advised that adequate hydration is necessary when 
taking TPM to minimize the risk of these unusual side-effects. 
It is also advisable to periodically measure serum bicarbonate 
levels in patients predisposed to acidosis.
Acute myopia and secondary angle-closure glaucoma 
syndrome are other possibilities (Fraunfelder et al 2004): 
these bilateral manifestations are rare, easily recognizable, 
and reversible following TPM withdrawal; prescreening is 
not recommended.
Effect on bodyweight
Weight gain is a common problem and concern in patients 
receiving treatments such as valproate, ﬂ  unarizine, and 
propranolol for migraine prevention. By contrast 60%–70% 
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Figure 1 Changes from baseline in migraine period frequency during controlled clinical 
trials (Brandes et al 2004; Diener et al 2004; Silberstein et al 2004): pooled data from 
patients receiving topiramate (TPM) 100 mg/day (Bussone et al 2005).
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Figure 2 Proportions of patients achieving at least 50% reduction and at least 75% 
reduction in monthly migraine period frequency during controlled clinical trials 
(Brandes et al 2004; Diener et al 2004; Silberstein et al 2004): pooled data from patients 
receiving topiramate (TPM) 100 mg/dayay (Bussone et al 2005).
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of patients on TPM in the MGR trials lost weight, and no 
change in bodyweight occurred in 20%. The mean overall 
reductions in baseline bodyweight in MIGR-001, MIGR-002, 
and MIGR-003 (Brandes et al 2004; Diener 2004; Silberstein 
et al 2004) were 3.8%, 3.3%, and 2.7% respectively.
Analysis of pooled data from these studies (Bussone et al 
2005; Silberstein et al 2005) showed that in patients receiving 
100 mg/day TPM, mean weight change was −2.5 kg, compared 
with virtually no change on placebo (+0.1 kg). In patients for 
whom data on body mass index (BMI) were available (n = 378), 
weight reduction was −1.9 kg in the patients with normal BMI, 
−3.1 kg in overweight patients, and −3.0 kg in obese patients.
Effect on quality of life
Improvement in HRQOL has been recently reported in an 
analysis of data pooled from the three MGR trials (Diamond 
et al 2005). The Migraine-Speciﬁ  c Questionnaire (MSQ, ver-
sion 2.1) (Jhingran et al 1998) was used to assess the effect 
of 100 mg/day TPM on HRQOL. This tool evaluates quality 
of life in three domains: role restriction (degree to which 
performance of daily activities is limited by migraine), role 
prevention (degree to which performance of daily activities is 
interrupted by migraine), and emotional function (examines 
feelings of frustration and helplessness due to migraine). All 
these domains improved signiﬁ  cantly more in TPM-treated 
patients than in those on placebo.
Contraindications
The available drugs for migraine prevention are characterized 
by diverse side-effect proﬁ  les and contraindications. On the 
basis of its lack of major contraindications, TPM can be used in 
the presence of various conditions that contraindicate the use 
of other migraine prophylactics: excess weight (amitriptyline, 
ﬂ  unarizine, pizotifen, valproate contraindicated); asthma 
(β-blockers absolutely contraindicated); depression (can 
be enhanced by ﬂ  unarizine and β-blockers); heart block, 
epilepsy, and urinary retention (amitriptyline contraindi-
cated); and liver disease and bleeding disorders (valproate 
contraindicated).
Concluding remarks
Migraine is a common chronic recurrent neurological 
disorder, associated with signiﬁ  cant morbidity, important 
impairment in daily functioning, and poor quality of life. 
Migraine patients with high attack frequency, severe and 
disabling attacks, poor response to acute treatment, or who 
overuse acute medications are candidates for prevention 
treatments.
Several compounds are currently used in migraine 
prophylaxis; in many of which efﬁ  cacy has not been deter-
mined in studies conducted according to the criteria of the 
International Headache Society (International Headache 
Society Clinical Trials Subcommittee 2000), or the recently 
published guidelines for assessing the clinical beneﬁ  ts of 
preventive agents in migraine patients (Silberstein 2000). 
By contrast, TPM satisfies these criteria, having being 
validated by large, double-blind, multicenter, cross-border, 
placebo-controlled trials that analyzed patients on an intent-
to-treat basis, and which lasted sufﬁ  ciently long (26 weeks) 
to assess adequately improvement and adverse events
Table 1 Most common adverse events in patients receiving different doses of topiramate (TPM) in controlled clinical trials (Brandes 
et al 2004; Diener et al 2004; Silberstein et al 2004): pooled data (Silberstein et al 2005)
TPM 50 mg/day TPM 100 mg/day TPM 200 mg/day Placebo
Adverse 
eventsa
Led to 
withdrawalb
Adverse 
events
Led to 
withdrawal
Adverse 
events
Led to 
withdrawal
Adverse 
events
Led to 
withdrawal
Paresthesia 35 3 51 8 49 7 6 1
Fatigue 14 3 15 5 19 5 11 1
Anorexia 9 1 15 2 14 6 3  1
Nausea 9 3 13 2 14 6 8 1
Dizziness 8 1 9 2 12 3 10 2
Taste perversion 15 0 8 0 12 0 1 0
Insomnia 6 2 7 3 6 3 5 1
Somnolence 8 1 7 2 10 2 5 2
Difﬁ  culty with memory 7 1 7 3 11 2 2 1
Language problems 7 2 6 2 7 2 2  1
aAdverse events: percentage of patients reporting each adverse event.
bLed to withdrawal: percentage of patients who withdrew from clinical trials due to each adverse event.Neuropsychiatric Disease and Treatment 2006:2(3) 266
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(Brandes et al 2004; Diener et al 2004, Silberstein et al 2004, 
2005; Bussone et al 2005).
These trials showed that TPM has sustained efﬁ  cacy 
associated with satisfactory safety and tolerability, 
particularly at the 100 mg/day dose. About half the patients 
receiving the target dose (100 mg/day) achieved at least a 
50% reduction in migraine frequency; a subgroup experi-
enced even greater clinical beneﬁ  t and about 6% became 
migraine free during the treatment period.
With regard to tolerability and safety, paresthesia is 
the most common adverse event, reported by about 50% 
of patients receiving 100 mg/day TPM. Analysis of the 
time course of this symptom in patients receiving TPM for 
migraine prevention showed that most paresthesias were 
transient, and about half had resolved by the end of the trial 
(Silberstein et al 2005). Nevertheless about 25% of patients 
on the 100 mg/day dose discontinued treatment for various 
reasons during the clinical trials.
We suggest that patients should be warned in advance of 
possible side-effects of TPM, and should be reassured about 
their benign and self-limited nature, and also because our 
clinical experience indicates that many patients will better 
tolerate them.
Other important characteristics of TPM are that 
efﬁ  cacy onset is usually rapid, progresses over time, and is 
independent of gender. Patient acceptability may be enhanced 
by lack of weight gain and lack of major contraindications, 
both of which are common concerns in patients receiving 
other preventive treatments for migraine. The effect on 
weight can be considered a favorable outcome in overweight 
or obese patients or in those on concomitant medications 
known to increase weight, such as antidepressants or atypical 
antipsychotics. TPM also has positive effects on quality of 
life. These positive attributes indicate that TPM can satisfy 
many migraine patients’ requirements as a prophylactic and 
so may contribute to reducing the negative impact of migraine 
on individuals and on society.
Experience with TPM in the treatment of epilepsy and 
migraine has shown that low initial dosing and slow titration 
increase tolerability. Our clinical experience is that by starting 
at 25 mg/day and increasing at 25 mg/week, it is possible 
to reach a maintenance dose of 50 mg bid in most patients, 
although slower titration may be necessary in some. It is also 
usually possible to increase the daily dose to 150 or 200 mg, 
if necessary.
TPM is already extensively used to treat migraine in 
clinical practice, both in the US and Europe. In a ques-
tionnaire survey of 30 headache specialists from various 
countries (Tepper et al 2004) conducted to determine 
practice with migraine prophylaxis, TPM was considered 
as ﬁ  rst-line or second-line treatment by many. We feel that 
the favorable clinical proﬁ  le of TPM, together with lack of 
major contraindications, suggest that the compound should 
be regarded as a ﬁ  rst-line treatment for the prevention of 
migraine.
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